IP Library › Patent Application 16372167
Patent Application
App. No. 16/372,167

ANTERIOR CHAMBER DRUG-ELUTING OCULAR IMPLANT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/372,167
Abstract

Disclosed herein are drug delivery ocular implants comprising an elongate outer shell having a proximal end, and distal end and being shaped to define an interior lumen, at least one therapeutic agent positioned within the lumen, wherein the outer shell has at least a first thickness, the outer shell comprises one or more regions of drug release, and the implant is dimensioned for implantation within the anterior chamber of the eye.

Claims (20)

1 .- 21 . (canceled)

22 . A drug delivery ocular implant comprising:

an outer shell having an open proximal end and a distal end, the outer shell being shaped to define an interior cavity;

at least one therapeutic agent positioned within the interior cavity;

a material covering the open proximal end, the material of increased permeability to the at least one therapeutic agent relative to a permeability of the outer shell; and

a retention protrusion is configured to retain the implant within an irido-corneal angle of an eye.

23 . The implant of claim 22 , wherein the retention protrusion comprises at least one ridge.

24 . The implant of claim 22 , wherein the at least one orifice is positioned on the proximal end of the outer shell.

25 . The implant of claim 22 , wherein the retention protrusion is positioned on the distal end of the outer shell.

26 . The implant of claim 22 , wherein the permeability of the material is configured to module a release rate of the at least one therapeutic agent.

27 . The implant of claim 22 , wherein the at least one therapeutic agent comprises one or more of prostaglandins, prostaglandin analogs, alpha-blockers, beta-blockers and combinations thereof.

28 . The implant of claim 27 , wherein said at least one therapeutic agent is selected from the group consisting of: latanoprost, travoprost, timolol, and brimonidine.

29 . The implant of claim 22 , wherein the therapeutic agent is an anti-vascular endothelial growth factor (anti-VEGF) drug.

30 . The implant of claim 29 , wherein the anti-VEGF drug is selected from the group consisting of: ranibizumab (LUCENTIS™), bevacizumab (AVASTIN™), pegaptanib (MACUGEN™), sunitinib, and sorafenib.

31 . The implant of claim 22 , wherein the retention protrusion is configured to anchor to an ocular tissue.

32 . The drug delivery ocular implant of claim 31 , wherein the ocular tissue comprises the sclera.

33 . The implant of claim 22 , wherein the implant is configured to elute the at least one therapeutic agent through the material for targeted delivery to the anterior chamber of the eye.

34 . The implant of claim 22 , wherein the implant is shaped and sized so as to be suitable for implantation within the anterior chamber of the eye.

35 . The implant of claim 22 , wherein the outer shell is biodegradable.

36 . The implant of claim 22 , wherein the material is biodegradable.